BROSSARD, Quebec, Sept. 03, 2025 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence ( ), announces a non-brokered private placement (“Private placement”) of 10 units (each a “Unit”) to be issued at a price of $10,000 per Unit for gross proceeds of $100,000.

Each Unit consists of: (i) One $10,000 unsecured convertible debenture (each a “Debenture”), and (ii) 10,000 stock warrants (each a “Warrant”).

Each Debenture has a term of 12 months (the “Term”) and bears interest at the annual rate of 10%, payable in cash. At the option of the holder of the Debenture, the principal amount may be converted, at any time d

See Full Page